NEUROBiOGEN

본문 바로가기 주메뉴 바로가기

Comunications

NEUROBIOGEN has been working with an advisory network of researchers and clinical
experts specializing in brain & neurological diseases with long experience.

News

News
Notice

News

Here are news on NEUROBIOGEN (currently in Korean only).

NO	SUBJECT	DATE	VIEW
89	Neurobiogen "Innovation Cost If Phase 1 Clinical Success..."I'm in phase 2 next year".	2023. 12. 15	380
88	CNR Research Applies for Phase 2 Pre-IND of Multi-Race Clinical Trials for Dementia/Obesity Treatment.	2023. 10. 04	406
87	CNR Research "U.S. FDA Pre-IND Application for Dementia and Obesity Treatment Substances".	2023. 10. 04	422
86	CNR Research Signs FDA Pre-IND Contract For Neurobiogen Dementia/Obesity Treatment.	2023. 10. 04	391
85	CNR Research Signs U.S. FDA Pre-IND With NeuroBiogen.	2023. 10. 04	521
84	CNR Research, Neurobiogen U.S. FDA Pre-IND Contract.	2023. 10. 04	401
83	CNR Research Signs U.S. FDA Pre-IND Agreement With NeuroBiogen.	2023. 10. 04	392
82	CNR Research, NeuroBiogen U.S. FDA Pre-IND Contract.	2023. 10. 04	399
81	Neurobiogen U.S. FDA Phase 2 Pre-IND Application.	2023. 10. 04	400
80	CNR Research Applies for New Obesity and Dementia Substances Neurobiogen U.S. FDA Pre-IND.	2023. 10. 04	374

1 2 3 4 5